Purple Biotech P/E Ratio

Purple Biotech (PPBT) currently reports a P/E ratio of -0.01. That is below the Healthcare sector average of 26.36. Use the charts on this page to explore Purple Biotech's P/E ratio history and peer comparisons.

Purple Biotech's P/E ratio of -0.01 is lower than the Healthcare sector average of 26.36. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Purple Biotech's market price to a fundamental measure such as earnings, sales, or book value. At -0.01, PPBT can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -0.01, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 26.36. From there, open related valuation or income-statement pages for Purple Biotech, and consider following PPBT for alerts when major investors trade the stock.

Purple Biotech is classified in the Healthcare sector. On P/E ratio, it currently shows -0.01 versus a sector average near 26.36. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PPBT with unrelated industries.